Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 10/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4978694 | 0.89 | KDM2B (0.52) | P2RX7ALDH1A1LMNAHRH1HRH3 | |
| SCHEMBL4980177 | 0.86 | KCNK3 (0.49) | P2RX7KDM4EALDH1A1LMNAL3MBTL1 | |
| SCHEMBL4977982 | 0.86 | KDM4E (0.53) | MEN1KMT2AP2RX7KDM4EALDH1A1 | |
| SCHEMBL4976331 | 0.85 | P2RX7 (0.47) | MEN1KMT2AP2RX7KDM4EALDH1A1 | |
| SCHEMBL4978542 | 0.85 | KDM4E (0.47) | MEN1KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL4974572 | 0.84 | P2RX7 (0.43) | P2RX7ALDH1A1L3MBTL1HRH1HRH3 | |
| SCHEMBL4976961 | 0.83 | HTT (0.53) | KDM4EALDH1A1L3MBTL1GRM5HRH3 | |
| SCHEMBL4976500 | 0.82 | P2RX7 (0.42) | MEN1KMT2AP2RX7LMNAL3MBTL1 | |
| SCHEMBL4978191 | 0.81 | GPR6 (0.41) | P2RX7KDM4EL3MBTL1HRH1HRH3 | |
| SCHEMBL4978912 | 0.81 | KDM4E (0.55) | MEN1KMT2AKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| WO-2007146122-A2 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | HRH3, HRH4, HRH2 | MEN1 4419/4885KMT2A 1417/4885P2RX7 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.